Evidence map›Paper›PMID 40247808›Full record

ArticleRecent patents on biotechnology2026

Extraction and Characterization of Iturin A as a Key Factor in the Antagonism of

Mahsa Aghaali Marnani, Mahboobeh Madani, Pegah Shakib

Abstract read
PubMed Publisher
In one paragraph

Article in Recent patents on biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mahsa Aghaali MarnaniDepartment of Microbiology, Falavarjan Branch, Islamic Azad University of Falavarjan, Isfahan, Iran.
Mahboobeh MadaniDepartment of Microbiology, Falavarjan Branch, Islamic Azad University of Falavarjan, Isfahan, Iran.
Pegah ShakibRazi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

objectivesThis research aimed to extract and characterize iturin A as the key antagonism factor of

methodsFor this study, Bacillus amyloliquefaciens strain M13-RW01 isolated from Isfahan soil was used. The lipopeptide compounds of B. amyloliquefaciens were examined for antagonistic performance against Aspergillus niger PTCC 5010, Mucor hiemalis PTCC 5292,

resultsHPLC analysis demonstrated that the lipopeptide compound is similar to iturin A. Moreover, MS analysis of these compounds and purified iturin A revealed a high similarity between them, with the same molecular ion peaks identified. Results showed that the produced lipopeptides by

conclusionAccording to the present study,

Indexed as

Antifungal AgentsBacillus amyloliquefaciensFungiLipopeptidesPeptides, CyclicAspergillus nigerChromatography, High Pressure LiquidFusariumMucorPatents as TopicPenicillium chrysogenumSoil MicrobiologyAntifungal Agentsiturin ALipopeptidesPeptides, CyclicBacillus amyloliquefaciensfarm cropsfungal germinationiturinlipopeptidemass spectrometry.methanolic fractionpathogenic fungi

Identifiers

PMID40247808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.